<DOC>
	<DOC>NCT02984995</DOC>
	<brief_summary>This is a Phase 2, multi-center, open-label, single-arm study to evaluate the efficacy, safety and pharmacokinetics of quizartinib monotherapy in Japanese subjects with FLT3-ITD positive refractory or relapsed acute myeloid leukemia.</brief_summary>
	<brief_title>Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>AML patients in first relapse or refractory after all prior therapy Presence of the FLT3ITD activating mutation in bone marrow or peripheral blood Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2 Diagnosis of acute promyelocytic leukemia AML secondary to prior chemotherapy for other neoplasms. Persistent, clinically significant &gt; Grade 1 nonhematologic toxicity from prior AML therapy Prior treatment with a FLT3 targeted therapy Active infection not well controlled by antibacterial, antifungal and/or antiviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>FLT3-ITD</keyword>
	<keyword>Positive refractory or relapsed acute myeloid leukemia</keyword>
	<keyword>Hematology malignancy</keyword>
	<keyword>Developmental Phase II</keyword>
</DOC>